Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Post Market

Current status date:

2021-12-06

Original market date: See footnote 1

2011-10-26

Lot number: See footnote 2

K62913

Expiry date: See footnote 2

2023-05-31

Product name:

RAPAFLO

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02361663

Product Monograph/Veterinary Labelling:

Date: 2018-03-12 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

ALLERGAN INC
300 1380 Rodick Road
Markham
Ontario
Canada L3R 4G5

Class:

Human

Dosage form(s):

Capsule

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

12:16.04.12 

Anatomical Therapeutic Chemical (ATC): See footnote 4

G04CA04 SILODOSIN

Active ingredient group (AIG) number:See footnote5

0152869001

List of active ingredient(s)
Active ingredient(s) Strength
SILODOSIN 4 MG
Version 4.0.2
Date modified: